Aditi Bhatt1, Pascal Rousset2, Nazim Benzerdjeb3, Praveen Kammar4, Sanket Mehta4, Loma Parikh5, Gaurav Goswami6, Sakina Shaikh1, Vahan Kepenekian7, Guillaume Passot7, Olivier Glehen8,9. 1. Department of Surgical Oncology, Zydus Hospital, Ahmedabad, India. 2. Department of Radiology, Centre Hospitalier Lyon-Sud, Lyon, France. 3. Department of Pathology, Centre Hospitalier Lyon-Sud, Lyon, France. 4. Department Surgical Oncology, Saifee Hospital, Mumbai, India. 5. Department of Pathology, Zydus Hospital, Ahmedabad, India. 6. Department of Radiology, Zydus Hospital, Ahmedabad, India. 7. Department of Surgical Oncology, Centre Hospitalier Lyon-Sud, Lyon, France. 8. Department of Surgical Oncology, Centre Hospitalier Lyon-Sud, Lyon, France. olivier.glehen@chu-lyon.fr. 9. Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Pierre Bénite, France. olivier.glehen@chu-lyon.fr.
Abstract
BACKGROUND: Patients undergoing cytoreductive surgery for colorectal peritoneal metastases who have a pathologic complete response (pCR) to neoadjuvant chemotherapy experience a significantly longer survival than those with residual disease. This response is known only after surgery. This study aimed to examine clinical and radiologic predictors of a pCR. METHODS: From July 2018 to December 2019, the study prospectively enrolled 120 patients. The clinical and radiologic findings were compared between patients with and without a pCR. A protocol for pathologic evaluation was followed. RESULTS: A pCR was observed in 34 patients (28.3%). Receiver operating characteristic (ROC) curves showed that patients with a surgical Peritoneal Cancer Index (sPCI) of 3 or lower had an 80% probability of experiencing a pCR, and that patients with a radiologic PCI (rPCI) of 2 or lower had a 70% probability of experiencing a pCR. A pCR was correctly predicted for 47% of the patients by imaging and for 44.4% of the patients by surgical evaluation. The site of primary tumor, the timing of peritoneal metastasis (PM), histology, tumor marker positivity, and mutations in known poor prognostic genes (KRAS) did not differ between the patients with and those without pCR. The primary tumor showed residual disease in 23.5% and regional nodes in 26.4% of the patients with pCR. CONCLUSIONS: The rPCI and sPCI concurred with a pCR in less than 50% of the patients. The patients with a lower PCI had greater concordance. An sPCI of 3 or lower was predictive of a pCR in 80% of the patients. The impact of KRAS mutations on pCR should be evaluated in a larger series. The predictors of pCR and response to systemic chemotherapy should be incorporated in prognostic scores used to select patients for surgery.
BACKGROUND:Patients undergoing cytoreductive surgery for colorectal peritoneal metastases who have a pathologic complete response (pCR) to neoadjuvant chemotherapy experience a significantly longer survival than those with residual disease. This response is known only after surgery. This study aimed to examine clinical and radiologic predictors of a pCR. METHODS: From July 2018 to December 2019, the study prospectively enrolled 120 patients. The clinical and radiologic findings were compared between patients with and without a pCR. A protocol for pathologic evaluation was followed. RESULTS: A pCR was observed in 34 patients (28.3%). Receiver operating characteristic (ROC) curves showed that patients with a surgical Peritoneal Cancer Index (sPCI) of 3 or lower had an 80% probability of experiencing a pCR, and that patients with a radiologic PCI (rPCI) of 2 or lower had a 70% probability of experiencing a pCR. A pCR was correctly predicted for 47% of the patients by imaging and for 44.4% of the patients by surgical evaluation. The site of primary tumor, the timing of peritoneal metastasis (PM), histology, tumor marker positivity, and mutations in known poor prognostic genes (KRAS) did not differ between the patients with and those without pCR. The primary tumor showed residual disease in 23.5% and regional nodes in 26.4% of the patients with pCR. CONCLUSIONS: The rPCI and sPCI concurred with a pCR in less than 50% of the patients. The patients with a lower PCI had greater concordance. An sPCI of 3 or lower was predictive of a pCR in 80% of the patients. The impact of KRAS mutations on pCR should be evaluated in a larger series. The predictors of pCR and response to systemic chemotherapy should be incorporated in prognostic scores used to select patients for surgery.
Authors: Y Berger; H Jacoby; M I Kaufmann; A Ben-Yaacov; G Westreich; I Sharon; L Barda; N Sharif; R Nadler; N Horesh; A Nissan; M Gutman; A Hoffman Journal: Ann Surg Oncol Date: 2019-02-11 Impact factor: 5.344
Authors: Darryl Schuitevoerder; Scott K Sherman; Francisco J Izquierdo; Oliver S Eng; Kiran K Turaga Journal: Ann Surg Oncol Date: 2020-07-06 Impact factor: 5.344
Authors: Lawrence H Schwartz; Saskia Litière; Elisabeth de Vries; Robert Ford; Stephen Gwyther; Sumithra Mandrekar; Lalitha Shankar; Jan Bogaerts; Alice Chen; Janet Dancey; Wendy Hayes; F Stephen Hodi; Otto S Hoekstra; Erich P Huang; Nancy Lin; Yan Liu; Patrick Therasse; Jedd D Wolchok; Lesley Seymour Journal: Eur J Cancer Date: 2016-05-14 Impact factor: 9.162
Authors: Geert A Simkens; Thijs R van Oudheusden; Daan Nieboer; Ewout W Steyerberg; Harm J Rutten; Misha D Luyer; Simon W Nienhuijs; Ignace H de Hingh Journal: Ann Surg Oncol Date: 2016-03-30 Impact factor: 5.344
Authors: Michael P Flood; Joseph C H Kong; Kasmira Wilson; Helen Mohan; Peadar S Waters; Jacob J McCormick; Satish K Warrier; Jeanne Tie; Robert Ramsay; Michael Michael; Alexander G Heriot Journal: Ann Surg Oncol Date: 2022-04-09 Impact factor: 4.339